Ovagen is a three-amino-acid compound from a Russian family of very short amino acid products, sold for liver and digestive support. No study has given Ovagen to a person; its results in the international literature are in cells and animals, and both were kidney rather than liver. Every listed benefit sits at the lowest level of confidence. The documented risks attach to how the product is obtained, not the compound. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Alanine aminotransferase (ALT) | 10–26 U/L (men), 8–22 U/L (women) | Most liver-specific enzyme; the primary response marker |
| Aspartate aminotransferase (AST) | 10–26 U/L | Pairs with ALT; a ratio above 1 points to alcohol or fibrosis |
| Gamma-glutamyl transferase (GGT) | Below 25 U/L (men), below 18 U/L (women) | Sensitive to alcohol, bile flow and oxidative load |
| Alkaline phosphatase (ALP) | 60–90 U/L | Detects bile obstruction, the main alternative explanation for liver symptoms |
| Total bilirubin | 0.4–1.0 mg/dL | Bile handling and red cell turnover |
| Albumin | 4.2–5.0 g/dL | Synthetic liver function; falls only with genuine impairment |
| Platelet count | 200–350 ×10⁹/L | A falling count is the earliest routine sign of portal hypertension |
| Fibrosis-4 index (FIB-4) | Below 1.30 | Calculated fibrosis screen; decides whether imaging is warranted |
| High-sensitivity C-reactive protein (hs-CRP) | Below 1.0 mg/L | Background inflammation that confounds liver enzyme readings |
| Estimated glomerular filtration rate (eGFR) | Above 90 mL/min/1.73 m² | Ovagen's only published cell data are renal, and its clearance is unstudied |
| Liver stiffness by transient elastography | Below 6.0 kPa | Direct fibrosis measure; the hard endpoint any liver claim must move |
| Ovagen-specific response marker | No established target exists; track the change from the individual's own pre-course values across the panel above | No validated biomarker of Ovagen activity has been defined |
Cadence: Baseline before the first course; liver panel at the end of each 10–20 day course, again 4 weeks later, then every 6–12 months while courses continue. Kidney function and elastography repeat annually; any value moving the wrong way is rechecked at 2 weeks.